[
  {
    "ts": null,
    "headline": "Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales",
    "summary": "LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), known as Merck in the U.S. and Canada, through a wholly owned subsidiary or a nominee, today announced that the High Court of Justice of England and Wales has approved the",
    "url": "https://finnhub.io/api/news?id=573d8914e3ef9fad50a1ea6b198e72cb967f01059ea7aa20de2221e010924213",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759781100,
      "headline": "Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales",
      "id": 136999039,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), known as Merck in the U.S. and Canada, through a wholly owned subsidiary or a nominee, today announced that the High Court of Justice of England and Wales has approved the",
      "url": "https://finnhub.io/api/news?id=573d8914e3ef9fad50a1ea6b198e72cb967f01059ea7aa20de2221e010924213"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Are Up. The Sector Is Looking Better Than It Has in Years.",
    "summary": "The  SPDR S&P Biotech  exchange-traded fund, which tracks a broad selection of biotech names, has shot up 8.9% since September 25, just more than a week ago.  The biotech run-up over the past week or so has been fueled by the same drug-pricing deal between  Pfizer  and President Donald Trump that set off a surge in Big Pharma share prices last Tuesday, along with a spate of acquisitions.  “Investors are naturally jittery, since prior rallies haven’t been sustained,” Cantor Fitzgerald analysts Josh Schimmer and Eric Schmidt wrote in a note on Friday.",
    "url": "https://finnhub.io/api/news?id=1a95ce3436e3b1e0658a591dd6e2f3d6e5e99a3906db105e7c009d2923a86cfc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759764780,
      "headline": "Biotech Stocks Are Up. The Sector Is Looking Better Than It Has in Years.",
      "id": 136989354,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The  SPDR S&P Biotech  exchange-traded fund, which tracks a broad selection of biotech names, has shot up 8.9% since September 25, just more than a week ago.  The biotech run-up over the past week or so has been fueled by the same drug-pricing deal between  Pfizer  and President Donald Trump that set off a surge in Big Pharma share prices last Tuesday, along with a spate of acquisitions.  “Investors are naturally jittery, since prior rallies haven’t been sustained,” Cantor Fitzgerald analysts Josh Schimmer and Eric Schmidt wrote in a note on Friday.",
      "url": "https://finnhub.io/api/news?id=1a95ce3436e3b1e0658a591dd6e2f3d6e5e99a3906db105e7c009d2923a86cfc"
    }
  },
  {
    "ts": null,
    "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
    "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
    "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759757340,
      "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
      "id": 136988239,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1146642361/image_1146642361.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
      "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk",
    "summary": "Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.",
    "url": "https://finnhub.io/api/news?id=f3d1e325c8979e5c256a781877a0e5161cf834c3f44fa173ef7dd8a98274314c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759755780,
      "headline": "Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk",
      "id": 136989147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.",
      "url": "https://finnhub.io/api/news?id=f3d1e325c8979e5c256a781877a0e5161cf834c3f44fa173ef7dd8a98274314c"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Merck Shares After Research Center Cuts and 13.5% Weekly Price Surge",
    "summary": "Trying to decide what to do with Merck’s stock right now? You are definitely not alone. After all, just in the past week, Merck’s shares have jumped 13.5%, a rapid turnaround when you consider the stock is still down 10.1% for the year and has dropped 14.8% over the past twelve months. The recent spike stands out after a long period of underperformance, catching the attention of investors looking for signals of a comeback or signs of shifting risk. What is driving this renewed momentum? A lot...",
    "url": "https://finnhub.io/api/news?id=c4d997d4934d1891605d382b3cda5f5f5911039fa02ffc09bebcfe16e5e9379e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759752729,
      "headline": "Assessing Merck Shares After Research Center Cuts and 13.5% Weekly Price Surge",
      "id": 136989357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Trying to decide what to do with Merck’s stock right now? You are definitely not alone. After all, just in the past week, Merck’s shares have jumped 13.5%, a rapid turnaround when you consider the stock is still down 10.1% for the year and has dropped 14.8% over the past twelve months. The recent spike stands out after a long period of underperformance, catching the attention of investors looking for signals of a comeback or signs of shifting risk. What is driving this renewed momentum? A lot...",
      "url": "https://finnhub.io/api/news?id=c4d997d4934d1891605d382b3cda5f5f5911039fa02ffc09bebcfe16e5e9379e"
    }
  },
  {
    "ts": null,
    "headline": "Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases",
    "summary": "RAHWAY, N.J., October 06, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in patients with three immune-mediated inflammatory diseases:",
    "url": "https://finnhub.io/api/news?id=bce39bba215951cbbbe6f103da200be02a13ab513d7e9dccee0a0f7a7f7a45ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759747500,
      "headline": "Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases",
      "id": 136989359,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 06, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in patients with three immune-mediated inflammatory diseases:",
      "url": "https://finnhub.io/api/news?id=bce39bba215951cbbbe6f103da200be02a13ab513d7e9dccee0a0f7a7f7a45ac"
    }
  },
  {
    "ts": null,
    "headline": "Merck launches three new trials on tulisokibart",
    "summary": "Merck announces the launch of three Phase 2b trials evaluating the safety and efficacy of tulisokibart , an investigational humanized monoclonal antibody targeting tumor necrosis factor -like...",
    "url": "https://finnhub.io/api/news?id=7bba01aa62a4556bd74d00b4ec4edbbf0d53c4dfe2054340a1084923dee94dda",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759738696,
      "headline": "Merck launches three new trials on tulisokibart",
      "id": 136987057,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces the launch of three Phase 2b trials evaluating the safety and efficacy of tulisokibart , an investigational humanized monoclonal antibody targeting tumor necrosis factor -like...",
      "url": "https://finnhub.io/api/news?id=7bba01aa62a4556bd74d00b4ec4edbbf0d53c4dfe2054340a1084923dee94dda"
    }
  }
]